216 related articles for article (PubMed ID: 35654829)
1. YAP inhibits ERα and ER
Li X; Zhuo S; Zhuang T; Cho YS; Wu G; Liu Y; Mu K; Zhang K; Su P; Yang Y; Zhang CC; Zhu J; Jiang J
Nat Commun; 2022 Jun; 13(1):3075. PubMed ID: 35654829
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER
Ma S; Tang T; Probst G; Konradi A; Jin C; Li F; Gutkind JS; Fu XD; Guan KL
Nat Commun; 2022 Feb; 13(1):1061. PubMed ID: 35217640
[TBL] [Abstract][Full Text] [Related]
3. YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth.
Li X; Zhuo S; Cho YS; Liu Y; Yang Y; Zhu J; Jiang J
EMBO J; 2023 Feb; 42(4):e112184. PubMed ID: 36588499
[TBL] [Abstract][Full Text] [Related]
4. A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer.
Zhu C; Li L; Zhang Z; Bi M; Wang H; Su W; Hernandez K; Liu P; Chen J; Chen M; Huang TH; Chen L; Liu Z
Mol Cell; 2019 Aug; 75(4):791-806.e8. PubMed ID: 31303470
[TBL] [Abstract][Full Text] [Related]
5. ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway.
Lin Y; Li C; Xiong W; Fan L; Pan H; Li Y
Cell Death Dis; 2021 Nov; 12(11):1042. PubMed ID: 34725332
[TBL] [Abstract][Full Text] [Related]
6. YAP, CTGF and Cyr61 are overexpressed in tamoxifen-resistant breast cancer and induce transcriptional repression of ERα.
Kim H; Son S; Ko Y; Lee JE; Kim S; Shin I
J Cell Sci; 2021 Jun; 134(11):. PubMed ID: 34096606
[TBL] [Abstract][Full Text] [Related]
7. RASSF1A-Mediated Suppression of Estrogen Receptor Alpha (ERα)-Driven Breast Cancer Cell Growth Depends on the Hippo-Kinases LATS1 and 2.
Roßwag S; Sleeman JP; Thaler S
Cells; 2021 Oct; 10(11):. PubMed ID: 34831091
[TBL] [Abstract][Full Text] [Related]
8. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
[TBL] [Abstract][Full Text] [Related]
9. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
10. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
12. KLF17 attenuates estrogen receptor α-mediated signaling by impeding ERα function on chromatin and determines response to endocrine therapy.
Ali A; Ielciu I; Alkreathy HM; Khan AA
Biochim Biophys Acta; 2016 Jul; 1859(7):883-95. PubMed ID: 27107895
[TBL] [Abstract][Full Text] [Related]
13. Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D
Lundqvist J; Kirkegaard T; Laenkholm AV; Duun-Henriksen AK; Bak M; Feldman D; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2018 Mar; 177():171-178. PubMed ID: 28610873
[TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
15. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
[TBL] [Abstract][Full Text] [Related]
16. USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α.
Cao J; Wu D; Wu G; Wang Y; Ren T; Wang Y; Lv Y; Sun W; Wang J; Qian C; He L; Yang K; Li H; Gu H
Cell Death Dis; 2021 Jun; 12(6):619. PubMed ID: 34131114
[TBL] [Abstract][Full Text] [Related]
17. Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
Wang M; Yan Q; Song Y; Zhang Z; Chen X; Gao K; Wan X
Oncogene; 2023 Jan; 42(4):322-334. PubMed ID: 36446891
[TBL] [Abstract][Full Text] [Related]
18. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.
Britschgi A; Duss S; Kim S; Couto JP; Brinkhaus H; Koren S; De Silva D; Mertz KD; Kaup D; Varga Z; Voshol H; Vissieres A; Leroy C; Roloff T; Stadler MB; Scheel CH; Miraglia LJ; Orth AP; Bonamy GM; Reddy VA; Bentires-Alj M
Nature; 2017 Jan; 541(7638):541-545. PubMed ID: 28068668
[TBL] [Abstract][Full Text] [Related]
19. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
20. The transcriptional regulators TAZ and YAP direct transforming growth factor β-induced tumorigenic phenotypes in breast cancer cells.
Hiemer SE; Szymaniak AD; Varelas X
J Biol Chem; 2014 May; 289(19):13461-74. PubMed ID: 24648515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
